Our COVID-19 pandemic update

Currently, we are not experiencing any supply issues. We are well prepared for situations like this, and we have a storage policy that ensures long-term delivery.

This is important as we are dealing with vital medicines that patients all over the world depend on every day.

We are aware that health authorities and pharmacies are doing their best to ensure the availability of vital medicines during COVID-19, and we can assure you that our current stock levels are normal. As we continue to monitor the situation, we will share our updates.

If you, or someone you know, is living with diabetes, obesity, or another serious chronic disease, there is no doubt you have some concerns. As many of us are being asked to stay home, there are many questions about both physical and mental concerns.

We want to share tips and suggestions we hope you will find useful.

Diabetes and COVID-19

Obesity and COVID-19

To protect the health and safety of our employees, we follow the advice and guidance from local health authorities. In some countries and communities where the risk of infection is still high, we are asking employees to work from home.

During these extraordinary working conditions, we are ensuring employees have support to keep active, work ergonomically from home and adopt to a digital workplace.

We are taking measures to keep employees working at our production sites safe and able to practice recommended social distancing when on the job.

We are continuing all of our already-initiated clinical trials and we do not expect significant delays in those that are close to finalisation. In the current situation, we are in close dialogue with trial investigators across the globe and we rely on their judgement to pause any ongoing trial recruitment and minimise patient visits to sites in order to coincide with regular medical care visits.

We also observe that trial follow-up is increasingly difficult, and we are working with relevant trial sites, investigators and authorities to find the best solutions in the situation. For ongoing trials, recruitment of new patients is negatively impacted, but gradually improving. It is now possible to initiate new trials in certain countries.